Best Oncology Companies in Sweden
The 110 best Oncology companies in Sweden in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Anocca.
Sweden's Oncology sector is one of the more interesting funding stories in European biotech right now, and this directory ranks the 110 companies we track here by disclosed equity raised and recent momentum. Total disclosed funding sits at $548M across the cohort, with Anocca alone accounting for $120M of that, which tells you a lot about how concentrated the capital is. The global oncology market is forecast to grow from roughly $250.9B in 2025 toward $668.3B by 2034 at an 11.5% CAGR, and the demand signals driving that, precision medicine, biomarker discovery, rising incidence rates, are exactly where Swedish companies are placing their bets. Cost-containment policies across European markets add friction, but they haven't slowed the deal flow here.
What's worth watching right now is the thematic shift underneath the funding numbers. Cancer biomarkers and angiogenesis inhibitors are generating serious coverage momentum this quarter, and AI's expanding role in oncology genetics is pulling investment toward companies with combinatorial data strategies. I'd also flag the Zydus-Assertio acquisition as a signal that oncology M&A appetite is live globally, which matters for exit optionality here. Almi Invest, EIC Fund and Flerie are the most active backers in this cohort. So if you're benchmarking Swedish oncology companies against each other, funding disclosed is your clearest starting point.
- Oncology Market Value to More Than Double, Reaching USD 748.17 Billion
- Pharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s contin
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Sweden
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Anocca Deevloper of personalized immunotherapeutics for oncology, autoimmune and inflammatory diseases | $120M | 10 mo ago | 100 | — | Apple iCloud MailMicrosoft 365Ruby+13 | — | — | — |
| 2 | Immunovia Developer of protein diagnostics devices for the early detection of cancer | $57M | 72 mo ago | 45 | Jeff Borcherding Chief Executive Officer | WordPressApple iCloud MailMicrosoft 365+30 | — | 173 patents Diagnostic biomarker arrays for cancer and autoimmune disease detection | 1 job opening · 1 launch |
| 3 | InDex Pharmaceuticals DNA-based immunomodulatory sequence medication for the treatment of inflammtatory bowel disease. | $45M | 81 mo ago | 7 | — | — | — | 252 patents Nucleic‑acid‑based gastrointestinal therapeutics, especially ulcerative colitis enema formulations. | — |
| 4 | Affibody Developer of antibody mimetic and protein based drug for the treatment of multiple diseases | $43M | 41 mo ago | 113 | — | WordPressMySQLPHP+18 | — | 422 patents Peptide therapeutics targeting cytokine/receptor pathways for immuno‑oncology and inflammation | 1 launch |
| 5 | Albireo Pharma Developer of novel bile acid modulators to treat gastrointestinal diseases | $40M | 165 mo ago | 3 | — | — | — | — | — |
| 6 | Asgard Therapeutics Developer of cancer immunotherapeutic solutions based on direct cell reprogramming | $40M | 27 mo ago | 7 | Cristiana Pires Co-Founder & CEO | WordPressMySQLPHP+17 | — | 36 patents Cellular reprogramming to dendritic/antigen‑presenting cells for cancer immunotherapy | 1 job opening · 1 award |
| 7 | Elypta Provider of liquid biopsy-based molecular diagnostics for cancer detection | $28M | 48 mo ago | 27 | Karl Bergman CEO | WebflowAmazon Web ServicesPlausible+10 | — | 25 patents Diagnostic biomarkers for cancer and arthritic disease detection and discrimination | 1 partnership |
| 8 | SciBase Provider of POC device for the detection of malignant melanoma | $22M | 60 mo ago | 22 | Stig Ollmar Founder | WordPressMySQLPHP+22 | 10 signals ▼17% Earnings · Capital raise · Contracts | 62 patents Electrical impedance measurement devices for tissue diagnostics and epithelial barrier analysis | — |
| 9 | One-carbon Therapeutics Developer of therapeutics to treat cancers, inflammation, and autoimmune diseases | $16M | 6 mo ago | 3 | — | — | — | — | — |
| 10 | Oasmia Company developing new drug formulations based on its nanoparticle based excipient technology | $14M | 80 mo ago | 19 | — | — | — | — | — |
| 11 | XNK Therapeutics Developer of cell-based immunotherapy for the treatment of cancer | $14M | 50 mo ago | 35 | Johan Liwing CEO | — | — | 10 patents Expanding natural killer cells for immunotherapy and related medical applications | — |
| 12 | Oblique Therapeutics Developer of antibodies and small molecules for the treatment of advanced and metastatic cancer | $12M | 67 mo ago | 23 | — | — | — | 126 patents TRPV1-targeted antibodies/epitope selection and sulfonyl‑pyridine oncology therapeutics | — |
| 13 | C-RAD Standalone oncology treatment clinic | $11M | 76 mo ago | 9 | Cecilia Leeuw CEO | WordPressMySQLPHP+29 | — | — | — |
| 14 | Alligator Bioscience Developer of antibody-based immunotherapies for the treatment of cancer | $10M | 92 mo ago | 61 | — | WordPress Block EditorWordPressMySQL+15 | — | 316 patents Immuno‑oncology therapeutics: antibody and peptide combination regimens targeting CD40. | — |
| 15 | Rarity Bioscience Developer of assays for diagnostics of cancer | $8M | 24 mo ago | 9 | Per Matsson Co-chair & co-founder | WordPressMySQLPHP+12 | — | 14 patents Sensitive nucleic acid detection assays using variant-specific probes and blocking agents | 2 awards |
| 16 | Ascelia Developer of orphan drugs for treatment and diagnostics solutions | $7M | 63 mo ago | 24 | — | WordPress Block EditorWordPressMySQL+12 | 3 signals Leadership · Announcements | — | — |
| 17 | Akiram Therapeutics Developer of radiopharmaceuticals for cancer treatment | $7M | 41 mo ago | 8 | — | — | — | 9 patents Therapeutic antibodies and binding proteins targeting CD44v6 for cancer treatment | — |
| 18 | Strike Pharma Developer of immuno therapeutics to treat cancer | $6M | 51 mo ago | 10 | Marten Winge Chief Executive Officer | WordPressMySQLPHP+14 | — | 31 patents Bispecific antibody/peptide conjugates and fusion proteins delivered via lipid nanoparticle carriers | — |
| 19 | 2A Pharma Developing vaccine using adeno-associated virus-like particle technology for cancer and infectious diseases. | $5M | 95 mo ago | 10 | Preben Bruun-Nyzell CEO | — | — | 10 patents Therapeutic parvovirus-derived proteins for autoimmune and HPV treatment | — |
| 20 | Beactica Develops small molecule drugs for oncology | $5M | 4 mo ago | 17 | — | Windows ServerMicrosoft ASP.NETIIS+5 | — | — | — |
| 21 | CLS Provider of image-guided laser ablation systems for focal therapy in the treatment of prostate cancer | $5M | 90 mo ago | 14 | Karl-Goran Tranberg Co-Founder | WordPressMySQLPHP+24 | 3 signals M&A · Earnings | — | — |
| 22 | Biovica Drug response monitoring assay | $4M | 54 mo ago | 13 | Anders Rylander CEO | WordPressMySQLPHP+17 | 11 signals Board · Earnings | — | — |
| 23 | iCellate Cancer profiling tool for precision oncology through liquid biopsy test | $4M | 36 mo ago | 19 | Pelle Redare Entrepreneur & Co-founder | — | — | — | — |
| 24 | Axelar Anti-cancer treatments that target the insulin-like growth factor-1 receptor signalling pathway | $4M | 67 mo ago | 8 | — | — | — | 79 patents Anticancer drug development: picropodophyllin polymorphs and cyclolignan synthesis/composition. | — |
| 25 | Elicera Developer of drugs for immuno-oncology | $3M | 16 mo ago | 2 | Di Yu Co-Founder | WebflowYouTubeShareThis+13 | — | — | — |
| 26 | Lipum Developer of antibody to treat juvenile idiopathic arthritis | $3M | 66 mo ago | 5 | Lennart Lundberg Co-Founder | — | — | 23 patents Therapeutic antibodies targeting bile‑salt‑stimulated lipase (BSSL) for cancer treatment | — |
| 27 | Oxcia Developing therapies targeting DNA Damage Response to cure cancer and inflammation | $3M | 39 mo ago | — | Ulrika Berglund CEO | — | — | — | 2 partnerships |
| 28 | Hamlet BioPharma Developer of drugs for the treatment of cancer and infections | $2M | 48 mo ago | — | Martin Erixon CEO | WordPressMySQLPHP+15 | — | — | — |
| 29 | Reccan Diagnostics Provider of protein biomarkers based in vitro diagnostics for solid cancers | $2M | 75 mo ago | — | Roland Andersson Co-Founder & CEO | — | — | 11 patents Early detection of pancreatic cancer using biomarker assay technologies | — |
| 30 | Cantargia Developer of antibody-based therapy for the treatment of solid tumors and cancers | $1M | 66 mo ago | 43 | Göran Forsberg CEO | WebflowNginxModernizr+5 | 10 signals ▲233% Leadership · Announcements · M&A | 113 patents IL1RAP-targeted therapeutic antibodies for oncology | — |
| 31 | Lithea Developer of bone mineral platform for local cancer drug delivery | $989K | 7 mo ago | — | Deepak Raina Co-Founder & CTO | — | — | — | — |
| 32 | Xintela Stem-cell technology for cartilage damage and brain tumors | $931K | 44 mo ago | 25 | — | WebflowTypekitjQuery+6 | — | 121 patents Stem cell markers and quality‑control for neural, chondrocyte, and mesenchymal regenerative therapies | — |
| 33 | Adduct Analys LC-MS based drug response blood test for precise dosing of CPA for breast cancer | $907K | 138 mo ago | — | Achim Orzechowski CEO | — | — | 8 patents Detection and characterization of N‑terminal protein adducts in proteomics | — |
| 34 | Kancera Developing small molecule therapeutics for Cancer | $898K | 94 mo ago | 4 | Thomas Olin CEO | WordPressMySQLPHP+11 | — | 122 patents Small‑molecule kinase and chemokine receptor antagonists plus stereoselective heterocyclic synthesis | — |
| 35 | AAX Biotech Developer of immunotherapies for cancer and autoimmune therapies | $685K | 4 mo ago | — | Maria Knudsen CEO | Cart FunctionalitySquarespace CommerceSquarespace+14 | — | 2 patents Therapeutic agent and target binding site discovery and design in biotechnology | — |
| 36 | CanImGuide Therapeutics Developing peptide therapeutics for cancer | $650K | 139 mo ago | 8 | Leif Hakansson CEO | — | — | 62 patents Peptide-based immune modulators and therapeutic formulations targeting immune regulation | — |
| 37 | BiBB Provider of biopsy instrument for the detection of cancerous tumors | $530K | 93 mo ago | 3 | Fredrik Lindblad CEO | WordPressMySQLPHP+7 | — | — | — |
| 38 | NEOGAP Developer of radiopharmaceuticals for the treatment of cancer | $473K | 4 mo ago | 21 | Samuel Svensson CEO | WordPressMySQLPHP+28 | — | — | — |
| 39 | Lead Biologics Developer of therapeutic antibodies against cancer | $259K | 10 mo ago | — | Thoas Fioretos Co-Founder | — | — | 5 patents Therapeutic and diagnostic antibodies targeting specific antigens | — |
| 40 | Genagon Therapeutics Developing antibodies for the treatment of cancer and inflammatory diseases | $233K | 124 mo ago | 10 | Simon Fredriksson Founder & CEO | — | — | 20 patents Targeted peptide therapeutics modulating CLPTM1 and TGF‑β signaling pathways | — |
| 41 | VOC Diagnostics Developer of diagnostic solutions to detect ovarian cancer | $198K | 73 mo ago | 3 | Gyorgy Horvath Founder | — | — | 8 patents Olfactory-based detection of ovarian cancer biomarkers via volatile compound analysis | — |
| 42 | Ectin Research Repurposing existing tropical drugs in combination therapeutics for bladder cancer and other indications | $165K | 106 mo ago | 1 | Marie-Lois Ivarsson Board Member & Co-Founder | — | — | — | — |
| 43 | Micropos Electromagnetic positioning system for Prostrate tracking during radiotherapy | $135K | 157 mo ago | 6 | — | WordPress Block EditorWordPress Site EditorWordPress+24 | — | — | — |
| 44 | ChemoTech Developer of electroporation devices for the treatment of cancer | $112K | 77 mo ago | 6 | Mohan Frick Founder & CEO | WordPressMySQLPHP+13 | — | — | — |
| 45 | Double Bond Pharmaceutical Provider of a pharmaceutical company developing innovative treatments for various diseases, including… | $112K | 79 mo ago | 10 | Igor Lokot CEO | — | — | 21 patents Patents concentrated in health & consumer products | — |
| 46 | FluoLink Developer of a fluorescence-based spectroscopy system to detect brain cancer | $107K | 87 mo ago | — | Johan Richter Co-Founder | — | — | 4 patents Optical biopsy guidance probes for tissue identification and harvesting | — |
Top 12 Oncology companies in Sweden
#1
Series D · Sodertalje, Stockholm County · founded 2014 · 100 employees$120Mraised▾
Developer of personalized immunotherapeutics for oncology, autoimmune and inflammatory diseases. The company has TCR-modified T-cell therapies against multiple antigen classes, tumours, genetic mutations, and viruses that cause cancer. The proprietary Immuno-technology platform for its target discovery, validation, and product development.
- Aug 2025Series D$46M
- May 2023Series C$36.9M
- Dec 2022Venture Debt$26.5M
- Jul 2021Series B$47M
#2
Series A · Uppsala, Uppsala County · founded 2006 · 17 employees$5.1Mraised▾
Beatica develops small molecule drug discovery platforms. Its proprietary platform is based on surface plasmon resonance and is designed to predict molecule - target interaction, especially when protein crystallization is not possible. The company offers lead optimization and other drug discovery services to pharma companies and research organizations. In addition, Beatica is planning to develop an internal pipeline of its own molecules as well.
- Feb 2026Grant (prize money)$3M
- Dec 2019Grant (prize money)$326.3K
- Jun 2019Series A—
- Sep 2018Grant (prize money)$58K
#3
Series B · Stockholm, Stockholm County · founded 2019 · 3 employees$16.2Mraised▾
Developer of therapeutics to treat cancers, inflammation, and autoimmune diseases. It offers one-carbon metabolism pathway-based therapeutics that target DNA repair and DNA damage response for the treatment of BRCA mutated cancer with PARP inhibitors.
- Dec 2025Series B$16.2M
#4
Seed · Stockholm, Stockholm County · founded 2020$684.9Kraised▾
Developer of immunotherapies for cancer and autoimmune therapies. It offers Seqitope an antibody epitope mapping method, Opti-mAb for CAR-T cells, and bispecific antibodies development for cancer treatment.
- Feb 2026Seed—
- Oct 2024Seed$684.9K
#5
Series A · Stockholm, Stockholm County · founded 2016 · 21 employees$473Kraised▾
Developer of radiopharmaceuticals for the treatment of cancer. The company has pTTL cell therapy product, which targets neoantigens by using proprietary PIOR and patented EpiTCer technologies, targeting neoantigens using immune cells from cancer patients as starting material.
- Feb 2026Series A$9.8M
- Mar 2024Seed$473K
- Nov 2023Grant (prize money)$2.6M
- 2023Grant (prize money)$8.9M
#6
Seed · Lund, Skane County · founded 2021$989.4Kraised▾
Developer of bone mineral platform for local cancer drug delivery. The platform facilitates controlled and sustained release of medication directly at the tumor site. This improves treatment outcomes and reduces side effects. The system uses biocompatible bone minerals to form a solid pellet implant. This implant delivers chemotherapy directly into tumor tissue. It increases local drug exposure while reducing harm to healthy tissue.
- Oct 2025Seed$989.4K
#7
Funding Raised · Landvetter, Vastra Gotaland County · founded 2007 · 2 employees$3.2Mraised▾
Elicera Therapeutics develops therapeutics, oncolytic virus and CAR-T cell-based therapies to treat cancer. The company has developed a platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) to optimize the drugs. The company has developed oncolytic virus AdVince (ELC-100) is a oncolytic genetically modified adenovirus (Ad5PTD) for killing neuroendocrine cancer cells (phase I/II-study) and CAR T-cell therapy ELC-301 for the treatment of Non-Hodgkin's B-cell lymphoma (phase I/II-study).
- Feb 2025Grant (prize money)$516.3K
- Jun 2022Grant (prize money)$2.7M
#8
Series A · Lund, Skane County · founded 2017 · 7 employees$39.8Mraised▾
Developer of cancer immunotherapeutic solutions based on direct cell reprogramming. The company has developed TrojanDC cancer immunotherapy by using dendritic cell reprogramming that has anti-tumor immunity power to suppress T-cell responses to cancers. It uses gene therapy-based technology that allows cancer cells to be immunogenic & unleashes the immune system against cancer.
- Mar 2024Series A$32.8M
- Jul 2023Grant (prize money)$81.9K
- Nov 2021Seed$6.9M
- May 2020Grant (prize money)$55.5K
#9
Seed · Lund, Skane County · founded 2022$259.2Kraised▾
Developer of therapeutic antibodies against cancer. It offers recombinant antibody technology to enhance immunotherapy which includes LB01 novel target for checkpoint inhibition in leukemia and solid tumors, LB02 target selectively expressed on leukemic cells, and LB03 an innate immune checkpoint inhibitor.
- Aug 2025Seed$259.2K
#10
Series A · Uppsala, Uppsala County · founded 2021 · 9 employees$7.5Mraised▾
Developer of assays for diagnostics of cancer. It offers molecular amplification technology to detect DNA sequence variants that are used to track cancer mutations in patients' tissue or liquid biopsies.
- Jun 2024Series A$7M
- Feb 2023Seed$539.6K
- Nov 2022Seed—
#11
Series D · Solna, Stockholm County · founded 1998 · 113 employees$43.3Mraised▾
Developer of antibody mimetic and protein based drug for the treatment of multiple diseases. Its proprietary technology platforms are Affibody molecules is used for developing antibody mimetics monoclonal antibodies and antibody fragments. The leading candidate of the company is for prevention of Alzheimers disease, autoimmune diseases, and psoriasis, along with diagnostic imaging program for metastatic breast cancer.
#12
Series A · Stockholm, Stockholm County · founded 2017 · 27 employees$27.9Mraised▾
Provider of liquid biopsy-based molecular diagnostics for cancer detection. The company offers a liquid biopsy platform for the detection and monitoring of the disease. The test is based on the measurement of various biomarkers. The test uses machine learning algorithms to generate a score against cancer-type specific signatures. The test is primarily meant for renal cell carcinoma. The test helps in early detection, differential diagnosis, and monitoring or prediction of treatment response, replacing or complementing medical imaging.
- Jun 2022Series A$21M
- May 2022Grant (prize money)$53.8K
- Dec 2019Seed$6.9M
- May 2019Grant (prize money)$2.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.